This suggests that decreasing the intracellular metabolism of ATRA, by inhibiting CYP26A1 activity using liarozole, might be a way to increase ATRA levels and augment RA signaling in tumor cells, including the reduction in tumor SC numbers in APC-mutant tissues. Here, CYP26A1 is linked to neoplasm.